HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
Access to Article
FROM
ISSUE
1507
Drugs for Menopausal Symptoms
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The primary symptoms of menopause are genitourinary and vasomotor. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar burning and irritation, pain during intercourse, and an increased risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep.

HORMONE THERAPY — Hormone therapy is the most effective treatment for menopausal vasomotor symptoms and the genitourinary syndrome of menopause (GSM).1,2

Estrogen – For women with GSM without vasomotor symptoms, low-dose vaginal estrogen products are preferred. All intravaginal formulations (see Table 1) are similarly effective for treatment of vulvovaginal atrophy. Because systemic absorption is low, vaginal estrogens generally do not relieve vasomotor symptoms, but they have a lower ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Menopausal Symptoms
Article code: 1507b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
© 2019 The Medical Letter, Inc.